Friday, September 18, 2020 Daily Archives

Gardasil scale-up unaffected by COVID capacity chase, says Merck

by

Merck says bringing two plants online to feed demand for its blockbuster Gardasil remains a priority, despite industry’s unparalleled need for vaccine capacity driven by COVID-19 projects. In January 2020, Merck & Co. (known as MSD outside North America) told delegates at the JP Morgan Conference in San Francisco that to keep up with the “incredible demand†for its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, two new production plants representing an investment of over $1.6 billion would come…

September 18, 2020

Lilly turns to Amgen to up COVID-19 antibody production

by

Amgen will provide manufacturing capacity to support scale-up of monoclonal antibody candidates being developed by Eli Lilly against COVID-19. Financial details of the deal have not been divulged but bringing fellow Big Pharma firm Amgen on board will “significantly increase the supply capacity available for Lilly’s potential COVID-19 therapies,†the firms said in a statement. “Increasing the manufacturing capacity for our neutralizing antibodies through this collaboration with Amgen is a crucial next step, and together we hope to be able…

September 18, 2020